PDCD1 and non-small cell lung carcinoma: Our patient populations included non-oncogene addicted NSCLC patients carrying tumors with a PD-L1 expression of less than 50%, who were treated with either immunotherapy alone as second line or anti-PD-1 pembrolizumab and platinum-based chemotherapy in front line.